Home
ACE Reports
All Specialties All Specialties All Specialties Arthroplasty Arthroplasty Arthroplasty Evidence Based Medicine Evidence Based Medicine Evidence Based Medicine Foot & Ankle Foot & Ankle Foot & Ankle General Orthopaedics General Orthopaedics General Orthopaedics Hand & Wrist Hand & Wrist Hand & Wrist Metabolic Disorders Metabolic Disorders Metabolic Disorders Osteoarthritis Osteoarthritis Osteoarthritis Pediatric Orthopaedics Pediatric Orthopaedics Pediatric Orthopaedics Peri-Operative Peri-Operative Peri-Operative Physical Therapy & Rehab Physical Therapy & Rehab Physio & Rehab Shoulder & Elbow Shoulder & Elbow Shoulder & Elbow Spine Spine Spine Sports Medicine Sports Medicine Sports Medicine Trauma Trauma Trauma Tumour Tumour Tumour Author Interviews Author Interviews Author Interview Conference Report Conference Report Conference Reports
Original Content
News
Multimedia
About
Search
Home
ACE Reports
Arthroplasty Evidence Based Medicine Foot & Ankle General Orthopaedics Hand & Wrist Metabolic Disorders Osteoarthritis Pediatric Orthopaedics Peri-Operative Physical Therapy & Rehab Shoulder & Elbow Spine Sports Medicine Trauma Tumour Author Interviews Conference Report
Original Content
News
Multimedia
About
Search
Previous Ace Report Continuous passive motion device offers effective relief of chronic low back pain Next Ace Report Continuous passive motion device offers effective relief of chronic low back pain
Ace Report Cover
Metabolic Disorders
Denosumab reduces secondary fragility fracture risk in osteoporotic women
Reprints
Cite This
Reprints
Cite This
AceReport Image
Metabolic Disorders
Denosumab reduces secondary fragility fracture risk in osteoporotic women
Climacteric. 2015 Jun 1:1-23
Contributing Authors

S Palacios L Kalouche-Khalil R Rizzoli C Zapalowski H Resc JD Adachi JC Gallagher RG Feldman DL Kendler A Wang RB Wagman S Adami

7808 osteoperotic women part of the FREEDOM study, were analyzed in this post-hoc analysis. The purpose of this study was to determine how efficacious denosumab (60mg for 36 months) was in preventing fragility fractures and secondary fragility fractures as compared to a placebo. Results indicated that prior fragility fracture was present in 45% of the population, and denosumab treatment significantly reduced the risk of fragility fracture and secondary fragility fracture regardless of subgroup.

Unlock the full article

Get unlimited access to OrthoEvidence with a free trial
Start Trial

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or continue reading this full article
Register Now
AskOE
Search
Close Search Window
Welcome Back!
Forgot Password?
Create an Account

Account will be affiliated with

OR
Forgot Password?
OR
Check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see the email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. Denosumab reduces secondary fragility fracture risk in osteoporotic women. ACE Report. 2015;5(11):2. Available from: https://myorthoevidence.com/AceReport/Report/

Copy Citation
Share this Ace Report